Recent Research from Leibniz University Highlight Findings in Vaccination (Modeling the cost-effectiveness of infant vaccination with pneumococcal…

Recent Research from Leibniz University Highlight Findings in Vaccination (Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany)

By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on Vaccination is the subject of a report. According to news reporting originating from Hannover, Germany, by NewsRx correspondents, research stated, "In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the cost-effectiveness of universal infant (< 2 years old) vaccination with a 13-valent pneumococcal conjugate vaccine (PCV13) in comparison with a 10-valent pneumococcal conjugate vaccine (PCV10) for the prevention of pneumococcal disease in Germany."

Our news editors obtained a quote from the research from Leibniz University, "A population-based Markov model was developed to estimate the impact of PCV13 and PCV10 on invasive pneumococcal disease (IPD), non-invasive pneumonia (PNE), and acute otitis media (AOM) over a time horizon of 50 years. The model included the effects of the historical vaccination scheme in infants as well as indirect herd effects and replacement disease. We used German epidemiological data to calculate episodes of IPD, PNE, and AOM, as well as direct and indirect effects of the vaccination. Parameter uncertainty was tested in univariate and probabilistic sensitivity analyses. In the base-case analysis, the ICER of PCV13 versus PCV10 infant vaccination was EUR 9826 per quality-adjusted life-year (QALY) gained or EUR 5490 per life-year (LY) gained from the societal perspective and EUR 3368 per QALY gained or EUR 1882 per LY gained from the perspective of the German statutory health insurance. The results were particularly sensitive to the magnitude of indirect effects of both vaccines."

According to the news editors, the research concluded: "Universal infant vaccination with PCV13 is likely to be a cost-effective intervention compared with PCV10 within the German health care system, if additional net indirect effects of PCV13 vaccination are significant."

For more information on this research see: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. European Journal of Health Economics, 2017;18(3):273-292. European Journal of Health Economics can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; European Journal of Health Economics - www.springerlink.com/content/1618-7598/)

The news editors report that additional information may be obtained by contacting A. Kuhlmann, Leibniz Univ Hannover, CHERH, D-30159 Hannover, Germany (see also Vaccination).

Keywords for this news article include: Hannover, Germany, Europe, Immunization and Public Health, Environment and Public Health, Communicable Disease Control, Pneumococcal, Epidemiology, Public Health Practice, Pneumococcal Disease, Risk and Prevention, Biological Products, Conjugate Vaccines, Synthetic Vaccines, Vaccination, Leibniz University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC